ADAMIS PHARMACEUTICALS CORP (ADMP)

US00547W3079 - Common Stock

0.7751  +0.01 (+0.86%)

After market: 0.77 -0.01 (-0.66%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022
Revenue
YoY % growth
2.78M
-87.43%
2.21M
-20.50%
4.76M
115.38%
EBITDA
YoY % growth
-28.07M
-7.59%
-30.63M
-9.12%
-23.58M
23.02%
EBIT
YoY % growth
-31.68M
-9.13%
-32.07M
-1.23%
-25.06M
21.86%
Operating Margin
-1,139.57%-1,451.13%-526.47%
EPS
YoY % growth
-0.62
-12.73%
-0.35
43.55%
N/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2022
Q2Q % growth
-0.06 -0.04-0.02-68.07%
Q1 2022
Q2Q % growth
-0.07
41.67%
-0.03-0.04-128.76%
Q4 2021
Q2Q % growth
-0.06
75.00%
-0.05-0.01-30.72%
Q3 2021
Q2Q % growth
-0.11
-10.00%
-0.04-0.07-169.61%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2022
Q2Q % growth
-50K
-103.91%
1.038M-1.088M-104.82%
Q1 2022
Q2Q % growth
1.15M
-17.27%
3.831M-2.681M-69.98%
Q4 2021
Q2Q % growth
-1.22M
-279.41%
2.874M-4.094M-142.45%
Q3 2021
Q2Q % growth
760K
-12.64%
1.42M-659.84K-46.47%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A